All News

How I use my medical identification bracelet to keep all those advance directive, contacts and doctor info connected to me.

The continuing contentious debate about screening for prostate cancer remains top of mind among the public and lay press.

In the hopes of recreating the successes achieved in other solid malignancies, researchers have evaluated many types of targeted therapy for the treatment of advanced gastric cancer.

Investigational monoclonal antibodies, such as daratumumab and elotuzumab, could potentially change the role of stem cell transplantation for patients with multiple myeloma.

Josh D. Lauring, of Johns Hopkins Medicine, is interested in identifying the genetic changes that drive breast cancer growth in order to determine novel therapeutic targets for drug development and ultimately improve outcomes for patients with breast cancer.

A potential biomarker called NRP-1 may indicate longer progression-free survival with tivozanib over Avastin for patients with metastatic colorectal cancer.

According to a recent analysis of a large national database, patients with a history of breast cancer have a higher risk of developing thyroid cancer than the general population, particularly if they receive adjuvant radiation therapy.

Exploring ways technology, connectivity and health data can make a difference for cancer patients.

Cancer research groups, Apple and breast cancer organizations partner to accelerate survivorship research.

I realized I couldn't be the only person so devastated by the effects and aftermath of cancer treatment. I decided to become a yoga teacher to help other patients and survivors.

CURE editor-in-chief and breast oncologist, Debu Tripathy, reviews the top breast cancer research highlights from 2014.

Living with advanced cancer has shifted how I view the passage of time and the growth of my children.

Kevin finally understands his place in the cancer universe.

MBCN offers advice for finding financial assistant for medical costs, daily living expenses and transportation to treatment.

Emmanuel S. Antonarakis explains data looking at AR-V7 and response to taxane therapy in men with metastatic castration-resistant prostate cancer.

The Food and Drug Administration has approved its first biosimilar, Zarxio (filgrastim-sndz), for all five of its counterpart Neupogen's authorized indications.

Treating patients with triple-negative breast cancer (TNBC) remains a challenge because these tumors do not rely on hormone receptors or HER2 amplification for tumor growth.

Results of a new study may help more lung cancer patients be eligible to participate in clinical trials.Researchers found that previously having cancer does not impact clinical outcomes in lung cancer patients.

Living in denial is sometimes not such a bad idea, especially when it comes to cancer.

The Food and Drug Administration has approved the anti–PD-1 agent Opdivo (nivolumab) for the treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). The approval comes three months ahead of the FDA's scheduled decision date.

With a growing number of people turning to social media for medical advice, it appears to be more important than ever for physicians to be contributing to the conversation.

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial.

Looking at prior treatment and efficacy data, researchers finds significant benefit with radiotherapy when given to older patients with hormone-negative invasive breast cancer who had undergone breast-conserving surgery.

A detailed tumor profile of molecular and protein alterations in a rare breast cancer subtype called metaplastic breast cancer, was one of the top studies presented at the Miami Breast Cancer Conference this year.

When a group of metastatic lung cancer patients took on the National Comprehensive Cancer Network and won.

The Food and Drug Administration (FDA) has granted a priority review to Opdivo for use in patients with previously treated, advanced, squamous non-small cell lung cancer (NSCLC). A decision will be made by June 22, 2015.

Now that the big day has arrived, what happens next? It may not be as exciting as advertised.

The management of patients with hormone receptor (HR)-positive breast cancer continues to evolve, with phase 3 studies shedding light on the length of adjuvant anti-estrogen therapy, a novel treatment gaining approval, and new trials exploring combination strategies.